Renal · Water Balance Disorders
The facts most likely to be tested
Nephrogenic diabetes insipidus is characterized by renal resistance to antidiuretic hormone (ADH), preventing the concentration of urine despite high circulating levels of the hormone.
The most common medication-induced cause of nephrogenic diabetes insipidus is chronic lithium therapy.
Patients present with polyuria and polydipsia associated with dilute urine and a low urine osmolality (<300 mOsm/kg).
The water deprivation test fails to increase urine osmolality, and the subsequent administration of desmopressin (dDAVP) results in no significant increase in urine concentration.
Serum hypernatremia and hyperosmolality develop if the patient does not have free access to water.
First-line management for drug-induced nephrogenic diabetes insipidus involves discontinuing the offending agent and ensuring adequate hydration.
If the underlying cause cannot be removed, treatment includes low-sodium diet, thiazide diuretics, or NSAIDs to increase proximal tubular water reabsorption.
Vignette unlocked
A 42-year-old male with a history of bipolar disorder presents to the clinic complaining of excessive thirst and frequent urination for the past three months. He reports drinking 6 liters of water daily. Physical examination is unremarkable, and his blood pressure is 125/80 mmHg. Laboratory studies reveal a serum sodium of 148 mEq/L and a urine osmolality of 150 mOsm/kg. A water deprivation test is performed, and his urine osmolality remains low despite rising serum osmolality; administration of desmopressin fails to increase urine concentration.
What is the most likely diagnosis and the most appropriate initial management step?
Nephrogenic diabetes insipidus; discontinue lithium.
The patient's failure to concentrate urine after desmopressin administration confirms nephrogenic DI, and his history of bipolar disorder strongly suggests lithium toxicity as the etiology.
Full handout
High yield triage
Etiology / Epidemiology
Caused by lithium toxicity or genetic V2 receptor mutations. Kidneys are resistant to ADH.
Clinical Manifestations
Presents with polyuria and polydipsia. Dilute urine with low specific gravity.
Diagnosis
Water deprivation test shows no increase in urine osmolality after desmopressin administration.
Treatment
Stop offending agent, thiazide diuretics, and low-sodium diet. Avoid dehydration.
Prognosis
Manageable with fluid intake; complications include hypernatremic dehydration.
Full handout
Epidemiology & Etiology
Most commonly acquired via chronic lithium therapy, which interferes with renal concentrating ability. Genetic forms involve mutations in the AVPR2 gene or AQP2 water channels. Other causes include hypercalcemia and hypokalemia.
Pertinent Anatomy
The collecting ducts of the nephron are the primary site of action for ADH (vasopressin). Under normal conditions, ADH triggers the insertion of aquaporin-2 channels into the apical membrane to facilitate water reabsorption.
Pathophysiology
Renal tubules fail to respond to circulating ADH, preventing water reabsorption despite high serum osmolality. This leads to the excretion of large volumes of hypotonic urine. The body cannot concentrate urine even when the patient is severely dehydrated.
Clinical Manifestations
Patients present with polyuria (>3L/day) and polydipsia (craving cold water). Physical exam may show signs of dehydration if access to water is restricted. Urine is characteristically dilute with a specific gravity <1.005.
Diagnosis
The water deprivation test is the gold standard; patients fail to concentrate urine despite rising serum osmolality. Administration of desmopressin (DDAVP) results in no change in urine osmolality, confirming the nephrogenic etiology. Serum sodium is often high-normal or elevated.
Treatment
Discontinue the offending agent (e.g., lithium). First-line therapy includes thiazide diuretics (e.g., hydrochlorothiazide) and a low-sodium diet to induce mild volume depletion and increase proximal tubule water reabsorption. NSAIDs (e.g., indomethacin) may be used as adjunctive therapy to decrease renal blood flow.
Prognosis
Prognosis is excellent if fluid access is maintained. The primary risk is hypernatremic dehydration during periods of illness or restricted access to water. Patients require regular monitoring of serum electrolytes.
Differential Diagnosis
Central DI: responds to desmopressin administration
Primary Polydipsia: low serum osmolality (<280 mOsm/kg)
Diabetes Mellitus: presence of glucosuria
Hypercalcemia: history of malignancy or hyperparathyroidism
Chronic Kidney Disease: elevated BUN/Creatinine